Evidence map›Paper›PMID 40399079›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with MET Amplification.

Takaaki Tanaka, Go Makimoto, Ryohei Sumii, Rika Omote, Yayoi Ando, Kiichiro Ninomiya, Eiki Ichihara, Kadoaki Ohashi, Yoshinobu Maeda, Masahiro Tabata

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takaaki TanakaDepartment of Respiratory Medicine, Okayama University Hospital, Japan.
Go MakimotoDepartment of Respiratory Medicine, Okayama University Hospital, Japan.
Ryohei SumiiDepartment of General Internal Medicine, NHO Fukuyama Medical Center, Japan.
Rika OmoteDepartment of Pathology, NHO Fukuyama Medical Center, Japan.
Yayoi AndoClinical Research Support Office, National Cancer Center Hospital, Japan.
Kiichiro NinomiyaCenter for Comprehensive Genomic Medicine, Okayama University Hospital, Japan.
Eiki IchiharaCenter for Clinical Oncology, Okayama University Hospital, Japan.
Kadoaki OhashiDepartment of Respiratory Medicine, Okayama University Hospital, Japan.
Yoshinobu MaedaDepartment of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan.
Masahiro TabataCenter for Clinical Oncology, Okayama University Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report describes a 70-year-old female with cancer of unknown primary origin (CUP) who exhibited multiple distant lymph node metastases. Despite conventional chemotherapy (carboplatin and paclitaxel) and immunotherapy (nivolumab), disease progression was noted. Genomic profiling revealed MET amplification, leading to the administration of capmatinib, a selective MET tyrosine kinase inhibitor. The patient experienced substantial tumor reduction with dose adjustments due to adverse effects, indicating the potential efficacy of capmatinib in treating CUP with MET amplification.

Indexed as

ImidazolesNeoplasms, Unknown PrimaryProto-Oncogene Proteins c-metAgedBenzamidesFemaleGene AmplificationHumansLymphatic MetastasisProtein Kinase InhibitorsTreatment OutcomeTriazinesBenzamidescapmatinibImidazolesMET protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-metTriazinescancer of unknown primarycapmatinibMET amplificationMET exon 14 skippingMET inhibitors

Identifiers

PMID40399079
PMCPMC12740391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.